Infliximab Biosimilar Drug Aliquot | Anti-TNF-α | Therapeutic Antibody

Aliquoted from the biosimilar drug | Now available for research use

Aliquots of the biosimilar Infliximab (Zessly®) are now available as research consumables.

Infliximab biosimilar drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available. The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Infliximab Biosimilar Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Zessly® - Infliximab Reference Product

Drug nameZessly®
INNInfliximab biosimilar
API typeInfliximab is a chimeric human-murine IgG1 monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
Pharmacotherapeutic groupImmunosuppressants, tumour necrosis factor alpha (TNFα) inhibitors
ATC codeL04AB02
Target of antibodyIgG1
General functionInfliximab can be used to treat Rheumatoid arthritis, Paediatric and adult Crohn’s disease,Paediatric and adult Ulcerative colitis, Ankylosing spondylitis, Psoriatic arthritis and Psoriasis.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFα but not to lymphotoxin α (TNFß).
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Infliximab inhibits the functional activity of TNFα in a wide variety of in vitro bioassays. Infliximab prevented disease in transgenic mice that develop polyarthritis as a result of constitutive expression of human TNFα and when administered after disease onset, it allowed eroded joints to heal. In vivo, infliximab rapidly forms stable complexes with human TNFα, a process that parallels the loss of TNFα bioactivity.
Original license holder
Marketing authorisation numbersEU/1/18/1280/001
Marketing authorisation holderSandoz GmbH Biochemiestr. 10 6250 Kundl Austria
Name of the manufacturer of the biological active substanceBoehringer Ingelheim Pharma GmbH & Co. KG Birkendorfer Strasse 65 88397 Biberach an der Riss GERMANY
Name and address of the manufacturer(s) responsible for batch releaseSandoz GmbH
Biochemiestr. 10
6336 Langkampfen
Max shelf life4 years
Storage conditions2°C – 8°C
List of excipientsDisodium succinate hexahydrate
Succinic acid
Polysorbate 80

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.